YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YIHCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,723,783 | $6,294,585 | $3,744,952 | $913,788 |
| % Growth | -40.8% | 68.1% | 309.8% | – |
| Cost of Goods Sold | $929,725 | $1,308,821 | $898,878 | $430,089 |
| Gross Profit | $2,794,058 | $4,985,764 | $2,846,074 | $483,699 |
| % Margin | 75% | 79.2% | 76% | 52.9% |
| R&D Expenses | $493,443 | $192,287 | $129,614 | $136,653 |
| G&A Expenses | $385,374 | $385,702 | $338,452 | $358,402 |
| SG&A Expenses | $1,539,368 | $1,939,479 | $1,551,047 | $883,245 |
| Sales & Mktg Exp. | $1,153,994 | $1,547,150 | $1,216,590 | $521,667 |
| Other Operating Expenses | $86,778 | $499,800 | $172 | $60 |
| Operating Expenses | $2,119,589 | $2,631,566 | $2,531,745 | $918,422 |
| Operating Income | $674,469 | $2,354,198 | $322,721 | -$458,106 |
| % Margin | 18.1% | 37.4% | 8.6% | -50.1% |
| Other Income/Exp. Net | -$97,236 | -$227,427 | -$281,646 | -$243,807 |
| Pre-Tax Income | $577,233 | $2,126,771 | $39,422 | -$667,184 |
| Tax Expense | $94,521 | $270,945 | -$9,817 | -$79,460 |
| Net Income | $482,712 | $1,992,624 | $76,603 | -$587,649 |
| % Margin | 13% | 31.7% | 2% | -64.3% |
| EPS | 0.55 | 2.26 | 0.087 | -0.67 |
| % Growth | -75.7% | 2,494.7% | 113% | – |
| EPS Diluted | 0.55 | 2.26 | 0.087 | -0.67 |
| Weighted Avg Shares Out | 879,968 | 881,692 | 879,968 | 877,088 |
| Weighted Avg Shares Out Dil | 879,968 | 879,968 | 879,968 | 879,968 |
| Supplemental Information | – | – | – | – |
| Interest Income | $70,279 | $57,775 | $6,739 | $11,346 |
| Interest Expense | $97,529 | $227,398 | $281,646 | $243,807 |
| Depreciation & Amortization | $395,660 | $391,274 | $377,357 | $259,816 |
| EBITDA | $1,070,422 | $2,745,443 | $691,483 | -$206,554 |
| % Margin | 28.7% | 43.6% | 18.5% | -22.6% |